Product Overview
Genestra DIM- 60 capsules
• Diindolylmethane (DIM) formulation • Provides 75 mg of 3,3’-diindolylmethane per day • Convenient vegetable capsule format • Vegan formula • Dairy-free, gluten-free
Each capsule of DIM provides 25 mg of 3,3’-diindolylmethane. The recommended daily dosage is 3 capsules.
Additional product info: In a clinical investigation, postmenopausal women aged 50-70 years old from Marin County, California, with a history of early-stage breast cancer, were screened for interest and eligibility in a pilot study on the effect of absorbable DIM (BioResponse-DIM®) supplements on urinary hormone metabolites. The treatment group received daily DIM (108 mg DIM/day) supplements for 30 days, and the control group received a placebo capsule daily for 30 days. Urinary metabolite analysis included 2-hydroxyestrone (2-OHE1), 16-alpha hydroxyestrone (16alpha-OHE1), DIM, estrone (El), estradiol(E2), estriol (E3), 6betahydroxycortisol (6beta-OHC), and cortisol in the first morning urine sample before intervention and 31 days after intervention. Nineteen women completed the study, for a total of 10 in the treatment group and 9 in the placebo group. DIM-treated subjects, relative to placebo, showed a significant increase in levels of 2-OHE1 (P=0. 020), DIM (P =0. 045), and cortisol (P = 0.039), and a non significant increase of 47% in the 2-OHE1/16alpha-OHE1 ratio from 1.46 to 2.14 (P=0.059). In this pilot study, DIM increased the 2-hydroxylation of estrogen urinary metabolites.(1)
A randomized, placebo-controlled, crossover study investigated the efficacy and safety of absorbable DIM in, pre-menopausal women with cyclical mastalgia at the dose of 60 mg/day. These subjects were given DIM or placebo for consecutive three months periods. Breast symptoms were monitored using daily entries on a "breast pain diary" as the assessment tool. Urine and blood samples were collected to confirm safety and the impact of DIM on estrogen metabolism. Results showed clinical improvement with DIM. A statistically significant reduction in duration of breast pain, severity of pain, swelling, and soreness accompanied absorbable DIM use. In addition, absorbable DIM was shown to increase the ratio of 2-hyroxy to 16-hydroxy estrone metabolites in urine. Supplementation with DIM was found to be an effective intervention for cyclical mastalgia.(2)
References: 1. Dalessandri K.M., Firestone G.L., Fitch M.D., Bradlow H.L. and Bjeldanes L.F. (2004) Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 50(2):161-167. 2. Zeligs MA, Brownstone PK, Sharp ME, Westerlind KC, Wilson SM, John SM (2005). Managing cyclical mastalgia with absorbable diindolylmethane: A randomized, placebo-controlled trial. JANA 8(1): 10-20
